Equity Profile

INCY

Incyte Corporation

Health CareBiotechnology$24.4B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Incyte Corporation (INCY) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $24 billion, it plays a significant role in the health care sector, particularly in oncology treatments.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $1.81

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

Incyte's last quarter saw an EPS of $1.81, significantly beating expectations. However, revenue details were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to exploring new treatment options in oncology.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Incyte's upcoming earnings, especially given its recent strong EPS performance.

Bull Case

If Incyte continues to beat EPS estimates and provides positive updates on its drug pipeline, it could see a strong stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing news about its pipeline, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.81

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

Pipeline Progress

Not available

Updates on clinical trials and new drug approvals can significantly impact the company's future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What updates will be provided on the drug pipeline?

Investors will closely watch for any news on clinical trials or new drug approvals, which are critical for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Incyte's potential for strong EPS growth based on its recent performance and pipeline advancements.

Supporting Evidence

Incyte has consistently beaten EPS estimates in recent quarters.

The options market is pricing in a significant move, indicating investor uncertainty that may not reflect the company's fundamentals.

Key Risk

If the EPS comes in significantly above expectations, it could shift the market's perception of Incyte's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Incyte's ability to sustain its recent earnings momentum and provide clarity on its growth prospects.

Bull Confirmed If

An EPS of $1.81 or higher would confirm the bullish sentiment and indicate strong financial health.

Bear Confirmed If

An EPS below $1.14 would signal potential issues and confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating heightened investor uncertainty.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests a potential stock increase of around +1.13%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a stock decline, with historical data suggesting an average drop of +0.18%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Details on revenue expectations for the upcoming quarters.
3Management's outlook on competitive pressures in the biotech sector.
4Insights into operational efficiencies and cost management strategies.
5Any commentary on potential new partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Expected to be around $1.81

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

Not available

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INCY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-36.50%

Avg Stock Reaction

+0.90%

Last Quarter Recap

Incyte's last quarter saw an EPS of $1.81, significantly beating expectations. However, revenue details were not disclosed, leaving some uncertainty.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to exploring new treatment options in oncology.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Incyte's upcoming earnings, especially given its recent strong EPS performance.

Bull Case

If Incyte continues to beat EPS estimates and provides positive updates on its drug pipeline, it could see a strong stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing news about its pipeline, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $1.81

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

Not available

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

Pipeline Progress

Not available

Updates on clinical trials and new drug approvals can significantly impact the company's future revenue potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

A strong EPS could reinforce investor confidence and lead to a positive stock reaction.

What updates will be provided on the drug pipeline?

Investors will closely watch for any news on clinical trials or new drug approvals, which are critical for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Incyte's potential for strong EPS growth based on its recent performance and pipeline advancements.

Supporting Evidence

Incyte has consistently beaten EPS estimates in recent quarters.

The options market is pricing in a significant move, indicating investor uncertainty that may not reflect the company's fundamentals.

Key Risk

If the EPS comes in significantly above expectations, it could shift the market's perception of Incyte's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Incyte's ability to sustain its recent earnings momentum and provide clarity on its growth prospects.

Bull Confirmed If

An EPS of $1.81 or higher would confirm the bullish sentiment and indicate strong financial health.

Bear Confirmed If

An EPS below $1.14 would signal potential issues and confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±15.51%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating heightened investor uncertainty.

Options are pricing ±15.5% while INCY has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

23.4%

Calls (7K)P/C Ratio: 0.07Puts (57K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Incyte beats expectations, history suggests a potential stock increase of around +1.13%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a stock decline, with historical data suggesting an average drop of +0.18%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Details on revenue expectations for the upcoming quarters.
3Management's outlook on competitive pressures in the biotech sector.
4Insights into operational efficiencies and cost management strategies.
5Any commentary on potential new partnerships or collaborations.